Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response

Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response

Summary: Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are innovative small target molecules that, in combination with endocrine therapy, have recently been employed in the treatment of patients with HR+/HER2− metastatic breast cancer (mBC). In this prospective study, we investigate...

Full description

Bibliographic Details
Main Authors: Fabio Scirocchi, Simone Scagnoli, Andrea Botticelli, Alessandra Di Filippo, Chiara Napoletano, Ilaria Grazia Zizzari, Lidia Strigari, Silverio Tomao, Enrico Cortesi, Aurelia Rughetti, Paolo Marchetti, Marianna Nuti
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:EBioMedicine
Subjects:
CDK4/6i
Regulatory T cells
Treg
Immune modulation
HR+/HER2- metastatic breast cancer
MDSCs
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396422001943

Internet

http://www.sciencedirect.com/science/article/pii/S2352396422001943

Similar Items